{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:52:19Z","timestamp":1772740339960,"version":"3.50.1"},"reference-count":56,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess and compare direct medical costs and medication compliance between patients with fibromyalgia who initiated duloxetine and patients with fibromyalgia who initiated pregabalin in 2008.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study design was used based on a large US national commercial claims database (2006 to 2009). Patients with fibromyalgia aged 18 to 64 who initiated duloxetine or pregabalin in 2008 and who had continuous health insurance 1\u00a0year preceding and 1\u00a0year following the initiation were selected into duloxetine cohort or pregabalin cohort based on their initiated agent. Medication compliance was measured by total supply days, medication possession ratio (<jats:styled-content style=\"fixed-case\">MPR<\/jats:styled-content>), and proportion of patients with MPR\u00a0\u2265\u00a00.8. Direct medical costs were measured by annual costs per patient and compared between the cohorts in the year following the initiation. Propensity score stratification and bootstrapping methods were used to adjust for distribution bias, as well as cross\u2010cohort differences in demographic, clinical and economic characteristics, and medication history prior to the initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both the duloxetine (<jats:italic>n<\/jats:italic>\u00a0=\u00a03,033) and pregabalin (<jats:italic>n<\/jats:italic>\u00a0=\u00a04,838) cohorts had a mean initiation age around 49\u00a0years, 89% were women. During the postindex year, compared to the pregabalin cohort, the duloxetine cohort had higher totally annual supply days (273.5 vs. 176.6, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), higher MPR (0.7 vs. 0.5, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), and more patients with MPR\u00a0\u2265\u00a00.8 (45.1% vs. 29.4%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). Further, relative to pregabalin cohort, duloxetine cohort had lower inpatient costs ($2,994.9 vs. $4,949.6, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), lower outpatient costs ($8,259.6 vs. $10,312.2, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), similar medication costs ($5,214.6 vs. $5,290.8, <jats:italic>P<\/jats:italic>\u00a0&gt;\u00a00.05), and lower total medical costs ($16,469.1 vs. $20,552.6, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05) in the postinitiation year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a real\u2010world setting, patients with fibromyalgia who initiated duloxetine in 2008 had better medication compliance and consumed less inpatient, outpatient, and total medical costs than those who initiated pregabalin.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12044","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T21:44:42Z","timestamp":1363297482000},"page":"22-31","source":"Crossref","is-referenced-by-count":11,"title":["Direct Medical Costs and Medication Compliance among Fibromyalgia Patients: Duloxetine Initiators vs. Pregabalin Initiators"],"prefix":"10.1111","volume":"14","author":[{"given":"Peter","family":"Sun","sequence":"first","affiliation":[{"name":"Kailo Research Group Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Peng","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Sun","sequence":"additional","affiliation":[{"name":"Kailo Research Group Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Novick","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Faries","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelaine M.","family":"Wohlreich","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wu","sequence":"additional","affiliation":[{"name":"Kailo Research Group Indianapolis IN U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390200142033"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0206"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.216"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.595734"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.605113"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00412.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.003"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.06.002"},{"key":"e_1_2_6_10_1","first-page":"519","article-title":"Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain","volume":"26","author":"Mas AJ","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600907949"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg199"},{"key":"e_1_2_6_13_1","first-page":"1520","article-title":"Prevalence of chronic fatigue syndrome and primary fibromyalgia syndrome in The Netherlands","volume":"141","author":"Bazelmans E","year":"1997","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_14_1","first-page":"1407","article-title":"The prevalence and meaning of fatigue in rheumatic disease","volume":"23","author":"Wolfe F","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_15_1","first-page":"543","article-title":"Epidemiological study of a primary fibromyalgia in pediatric age","volume":"48","author":"Sardini S","year":"1996","journal-title":"Minerva Pediatr"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"e_1_2_6_17_1","first-page":"525","article-title":"Fibromyalgia syndrome in children\u2013an outcome study","volume":"22","author":"Buskila D","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_18_1","unstructured":"NFA.Prevalence of Fibromyalgia.2009.http:\/\/www.fmaware.org\/site\/PageServer?pagename=fibromyalgia_affected(accessed May 5 2009)."},{"key":"e_1_2_6_19_1","unstructured":"WD.Prevalence and Incidence of Fibromyalgia.2009.http:\/\/www.wrongdiagnosis.com\/f\/fibromyalgia\/stats.htm(accessed May 5 2009)."},{"key":"e_1_2_6_20_1","unstructured":"NIAMS.Fibromyalgia.1999.http:\/\/www.niams.nih.gov\/Health_Info\/Fibromyalgia\/default.asp(accessed May 5 2009)."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_6_22_1","first-page":"81","article-title":"Fibromyalgia. Diagnosis and management","volume":"10","author":"Guymer EK","year":"2002","journal-title":"Australas Chiropr Osteopathy"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/959036"},{"key":"e_1_2_6_24_1","unstructured":"American Pain Society (APS); 2005. 109 p. Clinical practice guideline Glenview IL CS Buckhardt D Goldenberg L Crofford Guideline for the management of fibromyalgia syndrome pain in adults and children"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2009.01.006"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262040-00003"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20070200"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20070115"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282fb0268"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-24"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.024"},{"key":"e_1_2_6_32_1","first-page":"502","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease PJ","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.027"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.009"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-972572"},{"key":"e_1_2_6_36_1","first-page":"1975","article-title":"Efficacy of milnacipran in patients with fibromyalgia","volume":"32","author":"Gendreau RM","year":"2005","journal-title":"J Rheumatol."},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20983"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.06.031"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.622"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20485"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep432"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.01.002"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.629262"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00470.x"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00453.x"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00440.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90265-D"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2004.04003.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-005-0042-3"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1699-258X(05)72745-5"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-007-0214-4"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0212-6567(07)70880-6"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e31815cff4b"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01754.x"},{"key":"e_1_2_6_55_1","first-page":"295","article-title":"Fibromyalgia and psychiatric comorbidity: their effect on the quality of life patients","volume":"38","author":"Gonzalez E","year":"2010","journal-title":"Actas Esp Psiquiatr."},{"key":"e_1_2_6_56_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/NNR.0b013e31822bbdfa","article-title":"Fibromyalgia symptoms, physical function, and comorbidity in middle\u2010aged and older adults","volume":"60","author":"Shillam CR","year":"2011","journal-title":"Nurs Res"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:33:30Z","timestamp":1696242810000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/papr.12044"],"URL":"https:\/\/doi.org\/10.1111\/papr.12044","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}